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N
orovirus and rotavirus are viral pathogens that infect at mucosal surfaces and induce gastroenteritis, characterized by vomiting, diarrhea, and malaise (1, 2) . Viral gastroenteritis causes significant morbidity and mortality in children, the elderly, and immunocompromised persons, thus representing a substantial health care burden (3, 4) . Treatments for these illnesses have been limited thus far to symptomatic care, including rehydration, because currently there is no specific antiviral therapy for these viral pathogens. Lambda interferon (IFN-; also called type III IFN) is an antiviral cytokine that regulates viral infection at mucosal surfaces and in the liver and brain (5) (6) (7) (8) . Administration of recombinant IFN-can prevent and resolve viral infections in the gastrointestinal tract (8, 9) and at other sites in mice (10) . These effects are observed for murine norovirus (MNoV) in mice lacking adaptive immunity, thus representing sterilizing innate immunity in the intestine (8) . These studies indicate the potential for IFN-as a therapeutic for viral infections, including those causing gastroenteritis, in humans, including immunocompromised hosts (11) . Better understanding of the mechanisms by which this antiviral cytokine functions is essential to understanding basic mechanisms of intestinal control of viral infection and for potential therapeutic application in humans.
Binding of IFN-to its receptor, a heterodimer of interleukin-10R2 (IL-10R2) and IFNLR1 (12, 13) , induces an antiviral gene expression program similar to that induced by type I IFN, with substantial overlap in gene sets in vitro (10, 14, 15) . However, type I and III IFNs exhibit unique antiviral properties in vivo. Ifnlr1 Ϫ/Ϫ mice exhibit elevated intestinal tissue replication and enhanced fecal shedding of a persistent strain of MNoV (8, 16) , a model virus which allows for more tractable in vitro and in vivo analyses than human norovirus (reviewed in references 17 and 18). Recombinant IFN-treatment is sufficient to prevent and cure MNoV infection (8) . In contrast, mice deficient for Ifnar1 (the receptor for type I IFNs) show enhanced extraintestinal spread of virus, but levels of MNoV fecal shedding are comparable to those of wild-type mice (8, 16) . Similarly, IFNLR1 restricts growth in the epithelium and fecal shedding of reovirus, while IFNAR1 instead regulates reovirus growth in the lamina propria (19) . IFN-exhibits an antiviral role exclusive of type I IFNs against a murine rotavirus strain (9) but cooperates with type I IFNs to limit intestinal replication of a heterologous simian strain in neonatal but not adult mice (20) . These findings indicate the likely importance of tissue compartment-, development-, and cell type-specific effects of type I and III IFNs in vivo. These effects may be secondary to unique virulence factors that counter specific IFNs or to differential expression of the IFN receptors (21, 22) .
IFNAR1 is thought to be expressed ubiquitously and at especially high levels on cells of hematopoietic origin (reviewed in references 23 and 24), whereas expression of detectable IFNLR1 appears to be limited to mucosal epithelial cells (25) , human hepatocytes (6), and neutrophils (26) . Although IFNLR1 expression on peripheral leukocytes has also been reported, it does not appear to be functional (27) . Upon IFNtreatment, IFN-stimulated genes accumulate in intestinal epithelial cells (IECs), indicating functional IFNLR1 expression (9, 19, 20) . In contrast, in IECs of adult mice, IFNAR1 may be expressed at lower levels or alternately trafficked, such as only to the apical portion of the cell (9, 20) . Differential receptor expression thus could account for complementary roles for different IFNs in protection against systemic infection (type I) and infection of mucosal (type III) sites. Importantly, however, it has been reported that cells that do not express detectably high levels of IFNLR1, such as the endothelial cells of the blood-brain barrier, may still respond to endogenous and exogenous IFN-with protective antiviral effects (10) . Thus, to successfully identify the cell types required for the antiviral response to IFN-, analysis of receptor expression levels may be insufficient, and definitive resolution requires a genetic approach to selectively delete receptor expression in specific cell types.
To identify the cell types that respond to IFN-in vivo in the intestine, we generated mice with a conditional mutant allele for Ifnlr1 and crossed them to mice expressing Cre recombinase via the action of different cell type-specific promoters (Table 1) . Ifnlr1 was targeted in cell types expected to express high receptor levels (intestinal epithelial cells [25] and neutrophils [26] ) and cells that are known to be permissive for MNoV replication in tissue culture (macrophages and dendritic cells [35] ). Of all the cell types tested, only intestinal epithelial cells (IECs) required expression of Ifnlr1 for the antiviral effects of IFN-against MNoV. To show the generality of our findings, we demonstrated the importance of IEC expression of this receptor for control of reovirus infection. This is the first study to genetically define IFN--responsive cells in vivo in the context of two independent mucosal viral infections. This study also confirms that the cells required for responding to endogenous IFN-to attenuate MNoV infection are the same as those that respond to exogenous IFN-administration, including in the elicitation of sterilizing innate immunity.
RESULTS
Ifnlr1 is expressed in the epithelial fraction along the length of the gastrointestinal tract. Tissue from adult mice homozygous for a null mutation in Ifnlr1 (28) or wild-type controls was collected from sites along the intestine, lung, mesenteric lymph node (MLN), or spleen (Fig. 1A) . The small intestine was also dissociated into epithelial and lamina propria fractions as previously described (36) , and RNA was isolated from these fractions and tissues. Expression of Ifnlr1 was detected by quantitative real-time PCR of cDNA generated from these RNA samples. We found that Ifnlr1 was expressed along the length of the intestine and in the lung, as well as in systemic tissues, including MLN and spleen (Fig. 1B) . Intestinal Ifnlr1 expression was substantially enriched (at least 30-fold; P ϭ 0.0381) in the epithelial fraction compared to the lamina propria fraction (Fig. 1B) , consistent with previous reports (9, 25) . As expected, no transcript was detected in any tissue in Ifnlr1 Ϫ/Ϫ mice (Fig. 1B) . Ifnlr1 expression in the small and large intestine is significantly diminished in Ifnlr1 f/f -Villincre mice. Embryonic stem (ES) cells targeted with a construct containing sequences homologous to Ifnlr1, an FLP recombinant target (FRT)-flanked lacZ and neomycin cassette, and loxP sites flanking exon 2 were provided by the Wellcome Trust Sanger Institute ( Fig. 2A) . Mice derived from these ES cells were crossed with mice expressing Flp recombinase for deletion of the FRT-flanked cassette (38) , leaving a conditional allele of Ifnlr1, referred to as Ifnlr1 f ( Fig. 2A) . Following removal of the floxed region in cells expressing Cre, the resulting transcript is predicted to produce a truncated protein product (Fig. 2B ). For disruption in specific cell lineages, Ifnlr1 f/f mice were crossed with various Cre mouse lines (Table 1) . For each line, Cre(ϩ) Ifnlr1 f/f mice were compared to Cre(Ϫ) Ifnlr1 f/f littermates to assess the effects of cell type-specific deletion upon Ifnlr1 expression along the intestine and in extraintestinal tissues (Fig.  1A) . Ifnlr1 f/f -Villincre mice showed significantly diminished Ifnlr1 expression in the small and large intestine (Fig. 2C) . Fractionation of the small intestine into epithelial and lamina propria fractions revealed efficient deletion of Ifnlr1 in the epithelium of these mice (Fig. 2C ). In contrast, Ifnlr1 f/f -MRP8cre, Ifnlr1 f/f -LysMcre, and Ifnlr1 f/f -CD11ccre mice showed no alterations in intestinal Ifnlr1 expression at the level of the whole tissues tested (Fig. 2D , E, and F). Ifnlr1 f/f -MRP8cre, Ifnlr1 f/f -LysMcre, and Ifnlr1 f/f -CD11ccre mice did exhibit substantial depletion of Ifnlr1 in their respectively targeted cell types of neutrophils (ϳ85%), macrophages (ϳ91%), and dendritic cells (ϳ85%), consistent with a previous report (39) (Fig. 2D , E, and F). Expression of Ifnlr1 remained unchanged in lung, MLN, spleen, stomach, and duodenum in Ifnlr1 f/f -Villincre mice, indicating expression of Cre specific to distal small intestine and colon (Fig. 2C) , consistent with previous reports (29, 40) .
Expression of Ifnlr1 in intestinal epithelium regulates MNoV shedding and response to recombinant IFN-. Ifnlr1 Ϫ/Ϫ mice and wild-type controls were inoculated with CR6, a persistent strain of MNoV that replicates well in the intestine, is shed into the feces at readily detectable levels, and is sensitive to treatment with IFN-(8, 41). As described previously (8) , Ifnlr1 Ϫ/Ϫ mice allow higher levels of fecal MNoV shedding than do wild-type mice at early time points (Fig. 3A and G) and are insensitive to IFN-treatment, although this treatment terminates MNoV replication in wild-type mice (Fig. 3A) . These results were also observed in a novel Ifnlr1-deficient mouse model (Ifnlr1 fϪ/Ϫ ) ( Table 1 and Fig. 3B ). This assay was next applied to the four mouse strains with lineage-specific deletion of Ifnlr1 (Table 1) . Ifnlr1 f/f -Villincre mice phenocopied Ifnlr1 Ϫ/Ϫ and Ifnlr1 fϪ/Ϫ mice, exhibiting both elevated fecal shedding of MNoV and resistance to IFN-treatment (Fig. 3C) . In contrast, Ifnlr1 f/f -MRP8cre, Ifnlr1 f/f -LysMcre, and Ifnlr1 f/f -CD11ccre mice exhibited viral loads and response to IFN-equivalent to those of Ifnlr1 f/f controls (Fig. 3D , E, and F). At day 7 postinoculation, IFNLR1 regulated fecal shedding of MNoV, as seen by comparing wild-type and Ifnlr1 Ϫ/Ϫ levels (Fig. 3G) . Ifnlr1 f/f -Villincre mice allowed fecal shedding equivalent to Ifnlr1 Ϫ/Ϫ and Ifnlr1 fϪ/Ϫ mice, suggesting that control of MNoV fecal shedding can be fully accounted for by IFNLR1 in Villin-expressing cells (Fig. 3G) . Similarly, Ifnlr1 f/f -Villincre mice exhibited no difference in comparison to Ifnlr1 Ϫ/Ϫ and Ifnlr1 fϪ/Ϫ mice along the full time course of infection (Fig. 3H) .
Expression of Ifnlr1 in intestinal epithelium is essential for induction of IFN--mediated sterilizing innate immunity to MNoV infection. We previously reported that recombinant IFN-can cure persistently infected mice in the absence of adaptive immunity (8) . To determine whether expression of Ifnlr1 in IECs is required for IFN--mediated sterilizing innate immunity to persistent MNoV infection, we established (Fig. 5A and B) , consistent with a previous report using another strain of reovirus, type 3 Dearing (19). Control of reovirus was predominantly through the expression of IFNLR1 on IECs, as Ifnlr1 f/f -Villincre mice displayed increased titers of reovirus in small intestinal tissues as well as enhanced fecal shedding (Fig. 5A and B ). These results demonstrate that expression of IFNLR1 in epithelial cells is essential for the control of reovirus infection by IFN-in the gut and indicate that IFN-signaling in IECs is an antiviral mechanism common to multiple enteric viral pathogens.
Interferon-stimulated gene expression in the intestine depends upon the expression of Ifnlr1 in epithelial cells. Ileum and proximal colon tissues were isolated from wild-type (WT), Ifnlr1 Ϫ/Ϫ , Ifnlr1 f/f , and Ifnlr1 f/f -Villincre mice 1 day posttreatment with either PBS or IFN-. These tissues were then assessed for expression of canonical antiviral interferon-stimulated genes (ISGs) Oas1a (42), Ifit1 (43), and Ifi44 (44) (Fig. 6A 
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DISCUSSION
In this study, we found that IECs are the predominant cell type expressing Ifnlr1 in the small intestine and colon and that this cell type plays a major role in IFN--mediated antiviral immunity in the intestine. Antiviral immunity elicited by IFN-to enteric reovirus and norovirus infection depends upon IFNLR1 signaling in Villinpositive IECs. Using four mouse strains with lineage-specific deletion of Ifnlr1 to study persistent infection and IFN--mediated clearance, we found that only Ifnlr1 f/f -Villincre mice exhibited a complete phenocopy of Ifnlr1 Ϫ/Ϫ mice. Targeting Ifnlr1 in other cells, including dendritic cells, macrophages, and neutrophils, had no detectable effect on basal levels of viral shedding or IFN--mediated clearance of MNoV. The dominant IFN--dependent antiviral contribution by IECs also was confirmed with reovirus infection. In studies using reovirus T1L, we observed viral titers in the small intestine of Ifnlr1 f/f -Villincre mice increased comparably to those detected in Ifnlr1 Ϫ/Ϫ mice, although we cannot rule out a minor role for other IFN--responding cells in the ileum. Therefore, IECs are the functionally dominant IFN--responding cells for endogenous and exogenous IFN-control of viruses in the intestine. There is a clear correlation between IFN--mediated induction of antiviral ISGs and IEC expression of IFNLR1, suggesting that induction of ISGs in IECs is the mechanism by which IFN-exerts its antiviral effects.
Expression of Ifnlr1 mRNA throughout the gut and in other extraintestinal tissues (MLN, lung, and spleen) was quantified by qPCR analysis. In lamina propria cells, there were fewer than 500 copies of Ifnlr1 mRNA per 1 g total RNA. In contrast, IECs express The small intestine was resected from the pylorus to the cecum and sectioned into three equal parts, representing the duodenum, jejunum, and ileum. Titers are expressed as PFU per milliliter of tissue homogenate or gram of stool. n ϭ 6 to 8 mice per group, combined from two independent experiments, analyzed by one-way ANOVA followed by Tukey's multiple-comparison test; a P value of Ͻ0.001 was determined by ANOVA column factor for all tissues and stool. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ns, not significant. n ϭ 5 to 9 mice per group, combined from two independent experiments, analyzed by one-way ANOVA followed by Tukey's multiple-comparison test; a P value of Ͻ0.001 was determined by ANOVA column factor for all tissues. ***, P Ͻ 0.001; ns, not significant. more than 10,000 copies of Ifnlr1 mRNA per 1 g total RNA throughout the small intestine. Thus, IECs are the dominant Ifnlr1-expressing cells and function as the major IFN--responding cells for antiviral immunity in the intestine. In MLN, spleen, and lung, we detected comparable expression of Ifnlr1 mRNA. Villin-positive cells were not the major cell type responsible for Ifnlr1 expression in these tissues, and neither were neutrophils, dendritic cells, or macrophages. Therefore, there may exist some other cell types that are important for IFN-responses in these tissues. Lung epithelial cells, which do not express Villin, likely reflect a major source of Ifnlr1 in that tissue (29) . B or T cells, which have been reported to express Ifnlr1 even though they lack a robust response to IFN-, may account for Ifnlr1 expression in the MLN and spleen (27) . Another possible cellular source for this expression is endothelial cells, based on the report that blood-brain barrier endothelial cells respond to IFN-to restrict West Nile virus neuroinvasion (10) . Thus, it would be interesting to study the role of IFN-in extraintestinal tissues in control of other pathogens and define the IFN--responsive cell types in these contexts.
In some tissues, such as lung and vagina, there is redundancy between type I and III IFN-mediated antiviral responses. IFN-controls influenza virus, severe acute respiratory syndrome (SARS) coronavirus, respiratory syncytial virus infection in the lung (45) (46) (47) , and herpes simplex virus 2 (HSV-2) infection in the genital tract (48) , redundantly with type I IFNs. In the intestine, however, IFN--mediated antiviral immunity does not redundantly overlap type I IFNs (8, 9, 19) . Adult IECs have polarized apical IFNAR1 expression only at low levels (9), and although IECs in neonates exhibit robust STAT1 activation after type I IFN treatment, in adult mice they are largely unresponsive to type I IFN treatment in vivo (9, 19, 20) . Moreover, the expression level of Ifnlr1 mRNA is highly enriched in IECs but minimally detectable in other compartments of intestinal tissue ( Fig. 1 and 2 ). This study, bolstering previous findings of alternate cellular expression patterns for type I and III IFN receptors, helps explain why IFN--mediated immunity in the intestine is nonredundant with IFN-␣/␤ in adult mice, even though they may stimulate transcription of highly overlapping sets of antiviral genes (7, 20) . Our data support a role for IECs as sentinels for enteric virus infection via their response to compartment-specific IFN-signaling (19, 20) .
One of the important features of IFN--mediated immunity is its sterilizing activity against persistent MNoV infection in the absence of adaptive immunity (8) . We observed that persistent MNoV infection of Rag1 Ϫ/Ϫ Ifnlr1 f/f -Villincre mice was not resolved by IFN-treatment and showed increased viral titers in the stool, similar to our observations with Rag1 Ϫ/Ϫ Ifnlr1 Ϫ/Ϫ mice. Thus, IFN--mediated sterilizing innate immunity requires IEC expression of the receptor. Since only macrophages, dendritic cells, and B cells are known to be susceptible to MNoV infection in vitro (35, 49) , it is not clear how the IFN-response in IECs ablates persistent MNoV infection in the absence of adaptive immunity. One possible explanation is that there is a secondary trans-acting molecule induced by IFN-in IECs that clears MNoV in other cell types. A related study has demonstrated that rotavirus can be terminated by injecting IL-22 and IL-18 into Rag1 Ϫ/Ϫ mice, but this IL-22-and IL-18-mediated viral clearance does not induce IFNor Stat1 activation (50) . Thus, there may be multiple innate immunological mechanisms to resolve persistent viral infection in the absence of adaptive immunity. Identifying the effectors of IFN--mediated sterilizing immunity is an important area to pursue in IFNimmunology.
This study reveals that Ifnlr1 expression in IECs is required for control of enteric MNoV and reovirus infections. Using a genetic approach with conditional knockout mice, we identified IECs as the dominant cell type that responds to endogenous and exogenous IFN-to control enteric viruses. Understanding the identity of IFN--responsive cell types provides further insight into mechanisms that control enteric viruses and will enhance future development of IFN--mediated antiviral therapeutics.
